CRYOPORT INC
About CRYOPORT INC
Cryoport, Inc. (Nasdaq: CYRX) is a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, with an emphasis on regenerative medicine and cell & gene therapies. The company supports biopharmaceutical firms, CDMOs, CROs, developers, and researchers with services and products to minimize risk across the cold chain. It operates from 50 strategic locations worldwide and offers bio-logistics, bio-storage, bio-processing, and cryogenic systems. Founded in 1999 and headquartered in Brentwood, TN, it is a public company with over 1,000 employees.
- ๐ CRYOPORT INC
- ๐ Cryoport proxy: director votes, equity plan, 2026 outlook
- ๐ Cryoport - 2026 Company Profile, Funding, Competitors & Financials - Tracxn
- ๐ Cryoport - 2026 Company Profile, Team, Competitors & Financials - Tracxn
- ๐ Cryoport raises 2026 revenue guidance to $197M-$199M | CYRX 8-K Filing
Investors
Key highlights
- Public company (NASDAQ: CYRX) providing cold chain solutions for regenerative medicine.
- Completed multiple post-IPO raises totaling over $1B including $350M debt in 2021.
- Backed by Blackstone with 12 total funding rounds.
- Operates 50 global locations serving biopharma and cell/gene therapy markets.
- Reported 2026 revenue guidance of $197M-$199M.
Ask StreetZero about CRYOPORT INC
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account